Are lower MRPs on cancer drugs translating into affordable care?

1. At a Glance

• The National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% for 137 non-scheduled anti-cancer drugs. This cuts prices of nearly 900 cancer medicine brands by up to 70%–93% [1].
• Core debate: a lower MRP (Maximum Retail Price) does not by itself make comprehensive cancer care affordable. Diagnostics, hospital stays, surgery and radiotherapy all sit outside drug price control [1].
• Where does the margin go? The gap between the supply price and the patient price is captured by traders, intermediaries and, in some cases, hospitals. The argument is that these savings should go either to R&D or to patients [1].
• UPSC relevance: links drug pricing regulation (GS-II Health), out-of-pocket expenditure (OOPE), pharma R&D and industrial policy (GS-III), and the ethics of pricing life-saving medicines (GS-IV).

2. Why in the News

• NPPA order capping trade margins at 30% on 137 non-scheduled anti-cancer drugs, cutting prices of about 900 brands by up to 70–93% [1].
• Example price cut: one drug fell from ₹40,000 to ₹2,720 after the NPPA move [1].
• The Hindu "Parley"-style debate (Page 15, Chennai edition, 6 November 2026) between Indu Bhushan, the first CEO of Ayushman Bharat, and K.M. Gopakumar, a legal adviser and public health researcher, moderated by Bindu Shajan Perappadan [1].

3. Background & Evolution

• ‡ 1997: NPPA set up as an independent regulator to fix and revise prices of controlled drugs and enforce the Drugs (Prices Control) Order (DPCO).
• ‡ 2013: DPCO 2013 adopts market-based ceiling prices for scheduled drugs, i.e. those in the National List of Essential Medicines (NLEM).
• February 2019: NPPA brings 42 more cancer drugs under price control by capping trade margins at 30%. This was the pilot of the Trade Margin Rationalisation (TMR) approach [2].
• ‡ 2024: Union Budget 2024-25 cuts customs duty to nil on three cancer drugs (Trastuzumab Deruxtecan, Osimertinib, Durvalumab), and GST on them falls from 12% to 5%. NPPA then directs manufacturers to cut MRPs.
• 2026: TMR extended to 137 non-scheduled anti-cancer drugs, covering about 900 brands [1].

4. Core Static Facts

Key terms

• Scheduled drug: a drug in Schedule I of DPCO, which is drawn from the NLEM. A ceiling price is fixed directly (‡).
• Non-scheduled drug: a drug outside the NLEM. Normally only the annual increase is controlled, but trade margins can be capped under the extraordinary power (‡).
• Trade margin: the difference between the price at which the manufacturer sells to the first point of distribution and the MRP paid by the patient [1].

5. Multi-Dimensional Analysis

Economic

• Indian patients had been paying inflated prices. Indu Bhushan's view is that there is "considerable scope to rationalise medicine prices" [1].
• R&D trade-off: pharma firms need adequate incentives to invest in R&D, and R&D investment in India "remains low" [1].
• Margin capping takes money from distribution-chain rents, not from manufacturer price. So it can bring prices down while leaving the incentive to manufacture intact [1].

Social / Health Equity

• Cancer care costs are not just drug costs. Price regulation alone "might not be enough" for comprehensive care [1].
• ‡ Cancer is a leading cause of catastrophic health spending. A cheaper drug matters little to a patient who cannot get to a diagnostic or radiotherapy centre.

Governance / Ethical

• Capture by intermediaries: traders, intermediaries and some hospitals take a disproportionate share of the value. Hospital pharmacies can sell at MRP after buying at deep discounts [1].
• Pass-through problem: a lower MRP on paper helps patients only if retailers and hospitals actually comply. Enforcement and monitoring are needed.
• Ethics: pricing life-saving drugs raises a conflict between profit and the right to health, which links to Article 21 jurisprudence (‡).

Legal / Regulatory

• Using extraordinary powers for non-scheduled drugs is a stopgap. It is not a permanent part of the NLEM/DPCO framework (‡).
• ‡ Patented drugs: margin caps change little where the manufacturer's own base price is high. The more relevant tools here are compulsory licensing (Section 84, Patents Act, 1970) and price negotiation.

Administrative

• Delivery runs through Ayushman Bharat–PM-JAY package rates, state drug controllers and Jan Aushadhi outlets. The role of Ayushman Bharat's first CEO in the debate highlights the insurance-based route [1].

6. Recent Developments (last 12–18 months)

• 2026: NPPA caps trade margins at 30% on 137 non-scheduled anti-cancer drugs, covering about 900 brands, with price cuts of up to 70–93% [1].
• 6 Nov 2026: The Hindu publishes the expert debate questioning whether lower MRPs mean affordable care [1].
• ‡ Union Budget 2025-26: customs duty exemption extended to additional life-saving drugs, including cancer drugs.

7. Prelims Hooks

• NPPA capped trade margins at 30% for 137 non-scheduled anti-cancer drugs [1].
• The cap affects nearly 900 brands of cancer medicines [1].
• Price cuts reach up to 70%–93% [1].
• In one example, a drug's price fell from ₹40,000 to ₹2,720 [1].
• The first CEO of Ayushman Bharat was Indu Bhushan [1].
• In 2019, NPPA capped trade margins at 30% for 42 cancer drugs [2].
• The trade margin cap applies to non-scheduled drugs, meaning drugs outside the NLEM [1].
• ‡ NPPA works under the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers.
• ‡ DPCO 2013 is issued under the Essential Commodities Act, 1955, not the Drugs and Cosmetics Act, 1940.
• ‡ Para 19 of DPCO 2013 lets NPPA fix or cap prices of any drug in extraordinary circumstances / public interest.
• ‡ Non-scheduled drugs may not raise their MRP by more than 10% in 12 months.
• ‡ The three cancer drugs given customs duty exemption in 2024 were Trastuzumab Deruxtecan, Osimertinib and Durvalumab.

8. Why 'Up to 93% Cheaper' Is Not What Most Patients Will Pay

• "Up to" is the best case, not the usual case
• The government's own release says MRPs will fall by up to 70%, depending on each drug's current price structure [4]. The 93% figure is the most extreme case [1].
• In the 2019 pilot, prices fell by an average of about 50% across 526 brands [6].

• So the ₹40,000 → ₹2,720 example is an extreme case. It shows how inflated some margins were, but most patients will see much smaller cuts.

• Not every brand gets its new price on day one

• The cap covers about 900 brands [1]. NPPA's first list of revised MRPs covered only 543 brands, effective 9 November 2026 [5].

• The list will be updated on a continual basis [5]. Until a brand's new MRP is notified, a patient buying it has no fixed lower price to demand.

• The 2019 pilot gives the only savings figure we have

• The 42-drug cap saved patients about ₹984 crore a year [6].
• The 2026 releases give no rupee estimate of savings [4][5]. So there is no way yet to judge whether the bigger round delivers more than it promises.

9. The Drug Is Cheaper, but the Hospital Bill Is Not

• Families pay most cancer costs from their own pockets
• About 65% of spending on cancer care is out-of-pocket expenditure, or OOPE (money families pay directly, not covered by insurance or government). This figure is cited in an NPPA order [8].

• Studies cited in the same report found about 60% of households borrow money for cancer hospital stays, and about 32% depend on help from friends and relatives [8].

• A margin cap cuts only one line of the bill

• The cap lowers the MRP of the medicine. Tests, surgery, radiotherapy and hospital stay are not covered by drug price control at all [1].

• So a family whose biggest cost is radiotherapy or a long hospital stay gains very little.

• The scale of the problem is bigger than a price cut

• The WHO found that standard treatment for one type of early breast cancer (HER2-positive) would cost about 10 years of an average Indian's annual wages [8].
• Even a 50% cut on such a treatment still leaves it far beyond what most households can pay. That gap needs financing (insurance or public hospitals), not just pricing.

10. A Price Cap Is Only as Strong as NPPA's Power to Collect

• Companies that overcharge mostly do not pay back
• In August 2026, the Parliamentary Standing Committee on Chemicals and Fertilizers reviewed NPPA's work [7].

• It found that about 85% of the money NPPA has demanded from companies for overcharging, ₹8,526 crore as of 2025, is still unpaid [7].

• Why the money is stuck: court cases

• About 70% of the unpaid amount is tied up in litigation (court cases). Some cases have been pending for over 20 years [7].

• So a company that breaks the cap today may face no real cost for decades. That weakens the threat behind every new MRP order.

• The new cap adds to the same weak machinery

• The 2026 order adds about 900 brands to what NPPA must watch [1]. The overcharging record shows that issuing an order is easier than enforcing it [7].

11. Why Margin Caps Do Little for the Costliest New Drugs

• The cap touches only the gap above the company's price
• Trade margin is capped at 30% of MRP [4]. The manufacturer's own price is left untouched.

• If a company sells a drug to the distributor at a very high price, 30% on top of it is still very expensive.

• The new list includes exactly such high-cost drugs

• It covers immunotherapy drugs (medicines that help the body's own immune system fight cancer) used for over 20 types of cancer, plus Bevacizumab, Pegfilgrastim and Denosumab [4].

• For these drugs, the patient's cost depends mostly on the manufacturer's price, which the cap does not reach.

• Parliament has asked whether the method itself is enough

• The Standing Committee suggested that the Ministry examine bringing back cost-based pricing (fixing a price from the actual cost of making the drug) through changes in the law [7].
• It also noted that trade margin rationalisation has so far been run only as a pilot for some anti-cancer drugs [7]. In other words, it is still an experiment, not a settled system.

12. The Industry's Case: Will Price Caps Hurt New Drug Research?

• The strongest objection
• Drug companies need enough profit to invest in research and development (R&D). R&D spending in India is already low [1].

• Each new price control, the argument goes, signals that future profits can be taken away. That makes firms less willing to invest in new cancer drugs.

• Why it is weaker against this particular tool

• A margin cap takes money from the distribution chain (traders, intermediaries, some hospitals), not from the manufacturer's price [1].

• The 2019 pilot cut prices by about 50% on average while saving patients about ₹984 crore a year [6]. That money came out of distribution margins, not out of research budgets.

• What the objection gets right

• Because the cap does not touch the manufacturer's price, it also does not reduce the high prices of new patented drugs (see the section above).
• So India cannot make the newest cancer drugs affordable through margin caps alone. That is where the real fight between R&D and access happens, and it needs other tools such as negotiation or insurance.

13. What Should Follow, and Who Must Do It

• NPPA: make the overcharging penalty real
• The Standing Committee recommended a fast-track dispute resolution system for cases not yet in court, and a dedicated legal cell inside NPPA to clear old court cases quickly [7].

• Without this, the new MRP order has no penalty to back it up [7].

• NPPA: finish the brand list quickly and make it public

• Only 543 of about 900 brands had revised MRPs in the first list [5][1]. NPPA has said it will update the list on a continual basis [5].

• Patients and chemists can check prices only for brands that appear on the list.

• Department of Pharmaceuticals: decide the long-term method

• The Committee asked the Ministry to examine cost-based pricing through changes in the law [7].

• This would let India move beyond running trade margin caps as a pilot [7].

• Health financing must cover what pricing cannot

• About 65% of cancer care costs are paid out of pocket [8]. Most of that cost lies outside the drug bill [1].
• So insurance-based coverage, such as the route Indu Bhushan's Ayushman Bharat represents, has to carry the rest [1].

14. Anchors for Answers

• Data: About 65% of spending on cancer care is out-of-pocket; about 60% of households borrow money for cancer hospital stays [8]
• Data: 2019 trade margin cap on 42 drugs cut prices by about 50% on average across 526 brands and saved patients about ₹984 crore a year [6]
• Data: ₹8,526 crore demanded from companies for overcharging; about 85% unpaid, about 70% stuck in litigation [7]
• Data: WHO: one standard early breast cancer treatment costs about 10 years of average Indian annual wages [8]
• Report/Committee: Parliamentary Standing Committee on Chemicals and Fertilizers, review of NPPA (August 2026): fast-track dispute resolution, a legal cell inside NPPA, and a look at bringing back cost-based pricing [7]
• Law/Case: Drugs (Prices Control) Order, 2013: the trade margin cap uses its extraordinary 'public interest' power for non-scheduled drugs
• Scheme: Ayushman Bharat PM-JAY: insurance route to cover non-drug cancer costs (tests, surgery, radiotherapy) that price caps cannot reach [1]

15. Mains Relevance

• GS-II: issues relating to development and management of the social sector and services in Health; government policies and interventions.
• GS-III: Indian economy, industrial policy, and IPR (pharma R&D, patents).
• GS-IV: ethics in public policy, including access to essential medicines and conflicts of interest in healthcare.

Plausible question stems

1. "Price regulation of medicines is necessary but not sufficient for affordable cancer care in India." Critically examine this in the context of the recent NPPA trade margin rationalisation. (GS-II, 15 marks)
2. Discuss the trade-off between drug price control and incentives for pharmaceutical R&D in India. Suggest a balanced policy framework. (GS-III, 10 marks)
3. Large distribution margins on life-saving drugs raise both economic and ethical concerns. Analyse this with reference to the role of hospitals and intermediaries. (GS-II/IV, 15 marks)

16. Related Topics to Study Next

• DPCO 2013 and NLEM 2022: the legal architecture for scheduled and non-scheduled pricing.
• Ayushman Bharat–PM-JAY: insurance-based financing of cancer treatment, an alternative to price control.
• PM Bhartiya Janaushadhi Pariyojana: generic drug access through dedicated outlets.
• Compulsory licensing and Section 3(d), Patents Act (Novartis–Glivec case, 2013): access to patented cancer drugs.
• National Health Policy 2017 and OOPE data (National Health Accounts): the affordability baseline.
• PLI scheme for pharmaceuticals and the PRIP scheme for R&D: the R&D incentive side of the debate.
• Customs duty and GST cuts on life-saving drugs (Budgets 2024-25 and 2025-26): fiscal routes to lower prices.
• National Cancer Grid and NPCDCS / NP-NCD: care infrastructure beyond drugs.

17. NCERT Concepts to Revise

• Drugs (Prices Control) Order, 2013 (Economy): The legal order under which NPPA fixes ceiling prices and used Para 19 powers to cap cancer drug margins.
• Trade margin rationalisation (Economy): The exact tool used: capping the gap between distributor price and MRP without fixing manufacturer prices.
• Scheduled and non-scheduled drugs (Economy): The 30% margin cap applies to non-scheduled drugs; scheduled drugs get ceiling prices instead, a frequent exam trap.
• National Pharmaceutical Pricing Authority (Polity): The regulator behind the cap; know its 1997 non-statutory origin and parent department.
• Out-of-pocket expenditure (Economy): Explains why cheaper drugs alone may not make cancer care affordable when households pay directly for diagnostics and hospital care.
• Ayushman Bharat PM-JAY (Economy): Insurance-based alternative to price control for financing cancer treatment, linked to a debate participant.

18. Common Errors / Trap Areas

• Wrong ministry: NPPA sits under the Ministry of Chemicals & Fertilizers, not the Health Ministry. The Health Ministry handles the NLEM and CDSCO (‡).
• Scheduled vs non-scheduled: the 30% trade margin cap applies to non-scheduled drugs. Scheduled drugs get a ceiling price instead [1].
• Mixing up 2019 and 2026: the 42-drug cap was in 2019 [2]. The 137-drug cap with about 900 brands is the current one [1].
• Wrong parent Act: DPCO comes from the Essential Commodities Act, 1955, not the Drugs and Cosmetics Act, 1940 (‡).
• Equating a lower MRP with affordable care: treatment costs outside drugs, and margins captured by hospitals, can cancel out the MRP cut [1].